Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

S.C.P.C Investor Presentation 2023

Apr 19, 2023

51900_rns_2023-04-19_69b2bc24-37a4-4c52-a332-2d6efd38612d.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

==> picture [445 x 235] intentionally omitted <==

Standard Chem & Pharm Co., Ltd. Stock Symbol : 1720 2023 Investor Conference 04/20/2023

==> picture [280 x 75] intentionally omitted <==

免責聲明Safe Harbor Notice

==> picture [88 x 81] intentionally omitted <==

本次簡報與討論包含特定預測性的說明，而其內容有關於營運結果、財務狀況，以及對未來事 件的預期。因為此等前瞻性說明是有關於未來事件，而且取決於未來發生時的環境因素，所以必 然含有風險與不確定性。

本公司將不負擔公開更新或修改這些預測性的說明之義務，無論是出現新資訊、未來發生任何 事件，或其他情況。實際結果可能與此等預測性說明推測的內容有重大差異。

In these presentations and discussions, there are certain forward looking statements regarding the results of operation, financial condition and current expectation about future events. As forward-looking statements relate to events and depend on circumstances in the future, they involve risk and uncertainty.

We do not undertake any obligation to publicly revise or update any forward looking statements for availability of new information, future events or otherwise. Real result probably differ substantially from those expected in these forward-looking statements.

© 2023 SCP, Ltd

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

1
----- End of picture text -----

==> picture [229 x 475] intentionally omitted <==

----- Start of picture text -----

© 2023 SCP, Ltd
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

Agenda

Introduction of Standard Group

2022 Operating Results

Future Operation StrategyCorporate Social Responsibility (CSR)

2

==> picture [229 x 475] intentionally omitted <==

----- Start of picture text -----

© 2023 SCP, Ltd
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

Agenda

Introduction of Standard Group

2022 Operating ResultsFuture Operation StrategyCorporate Social Responsibility (CSR)

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

3
----- End of picture text -----

==> picture [815 x 474] intentionally omitted <==

----- Start of picture text -----

SCP and Related/Affiliated Com anies
p
Upstream Manufacture Channels
Syn-Tech (1982; 2005 SCP(1967;
Taiwan Biosim(2017)
Over-The-Counter (OTC)) 1995 listed stock)
Western
medicine
Your Chance
Syngen(1999; 2016 OTC) Souriree(1997) (Invested in 2013;
2022 Pioneer Stock Board (PSB))
Multipower
Syngen(1999)
Healthcare (Invested in 2012)
nutrition
Sun-you(1994) Advpharma (1999)
Medical- Syngen (1999)
devices
Q
Ho Yao Biopharm
Gene chip Advpharma (1999) (2021)
Inforight(2000)
4
Software/Hardware
© 2023 SCP, Ltd service support
----- End of picture text -----

International Accreditation

==> picture [606 x 32] intentionally omitted <==

----- Start of picture text -----

1998 2000 2008 2009 2010 2017 2021
----- End of picture text -----

==> picture [42 x 45] intentionally omitted <==

==> picture [29 x 38] intentionally omitted <==

The first TW pharmaceutical company to be ISO9001 certified

==> picture [50 x 32] intentionally omitted <==

==> picture [46 x 25] intentionally omitted <==

The first TW company to pass US FDA inspection in 2000

Subsequent US FDA GMP inspections : no 483 Last Inspection : 2022/10/31

==> picture [28 x 37] intentionally omitted <==

SCP received JP PMDA’s FDF Plant and API Plant passed “Certificate of Foreign Drug PMDA GMP Audit in 2018 Manufacturer” in 2008

==> picture [50 x 31] intentionally omitted <==

==> picture [58 x 37] intentionally omitted <==

2009

==> picture [48 x 33] intentionally omitted <==

SCP’s API plant passed AU TGA inspection

==> picture [44 x 34] intentionally omitted <==

==> picture [48 x 36] intentionally omitted <==

2010 SCP passed TW PIC/S GMP inspection 2012 SCP is certified GDP by the T-FDA

==> picture [49 x 33] intentionally omitted <==

==> picture [70 x 31] intentionally omitted <==

2012 SCP passed K-FDA inspection

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

Q

45

© 2023 SCP, Ltd

==> picture [229 x 475] intentionally omitted <==

----- Start of picture text -----

© 2023 SCP, Ltd
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

Agenda

Introduction of Standard Group

2022 Operating Results

Future Operation StrategyCorporate Social Responsibility (CSR)

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

6
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

Consolidated Income Statement

Items 2022 2021 Diff. Annual
changes (%)		 Q
(Unless otherwise specified, expressed in thousands
of New Taiwan Dollars)
Operating revenue 5,851,368 4,604,082 1,247,286 27.1%
Gross profit 2,487,613 2,067,873 419,740 20.3%
Gross profit margin 42.3% 44.9% -2.6pct
Operating expenses 1,369,192 1,191,191 178,001 14.9%
Operating profit 1,118,421 876,682 241,739 27.6%
Non-operating income and expenses 281,512 137,068 144,444 105.4%
Profit before income tax 1,399,933 1,013,750 386,183 38.1%
Profit for the year 1,153,620 836,802 316,818 37.9%
Profit attributable to Shareholders of
the parent
815,408		 706,734 108,674 15.4%
EPS(NTD) 4.56 3.95 0.61 15.4%
©2023 SCP, Ltd
Note: SYN-TECH is consolidated into the financial report of the group in December, 2021. In 2022, the gross profit margin of
SYN-TECH at 37.3% caused the overall gross profit margin of the Company to decrease compared to the same period in 2021

Note: SYN-TECH is consolidated into the financial report of the group in December, 2021. In 2022, the gross profit margin of SYN-TECH at 37.3% caused the overall gross profit margin of the Company to decrease compared to the same period in 2021.

7

© 2023 SCP, Ltd

Comparison of Quarterly Revenue of Past 5 Years
(Consolidated)
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
1,400,000
1,600,000
2018
2019
2020
2021
2022
Expressed in thousands of NTD
Q
Q1
Q2
Q3
Q4
Total
Growth(%)
2018
763,261
897,693
913,353
998,786
3,573,093
-7.2%
2019
846,177
1,010,837
1,048,886
1,031,229
3,937,129
+10.2%
2020
1,034,417
1,108,059
1,045,351
1,117,573
4,305,400
+9.4%
2021
1,101,113
1,149,060
1,120,840
1,233,069
4,604,082
+6.9%
2022
1,237,170
1,481,061
1,549,872
1,583,265
5,851,368
+27.1%
18 19 20 21 22
18 19 20 21 22
18 19 20 21
18 19 20 21 22
22		 Comparison of Quarterly Revenue of Past 5 Years
(Consolidated)
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
1,400,000
1,600,000
2018
2019
2020
2021
2022
Expressed in thousands of NTD
Q
Q1
Q2
Q3
Q4
Total
Growth(%)
2018
763,261
897,693
913,353
998,786
3,573,093
-7.2%
2019
846,177
1,010,837
1,048,886
1,031,229
3,937,129
+10.2%
2020
1,034,417
1,108,059
1,045,351
1,117,573
4,305,400
+9.4%
2021
1,101,113
1,149,060
1,120,840
1,233,069
4,604,082
+6.9%
2022
1,237,170
1,481,061
1,549,872
1,583,265
5,851,368
+27.1%
18 19 20 21 22
18 19 20 21 22
18 19 20 21
18 19 20 21 22
22		 Comparison of Quarterly Revenue of Past 5 Years
(Consolidated)
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
1,400,000
1,600,000
2018
2019
2020
2021
2022
Expressed in thousands of NTD
Q
Q1
Q2
Q3
Q4
Total
Growth(%)
2018
763,261
897,693
913,353
998,786
3,573,093
-7.2%
2019
846,177
1,010,837
1,048,886
1,031,229
3,937,129
+10.2%
2020
1,034,417
1,108,059
1,045,351
1,117,573
4,305,400
+9.4%
2021
1,101,113
1,149,060
1,120,840
1,233,069
4,604,082
+6.9%
2022
1,237,170
1,481,061
1,549,872
1,583,265
5,851,368
+27.1%
18 19 20 21 22
18 19 20 21 22
18 19 20 21
18 19 20 21 22
22		 Comparison of Quarterly Revenue of Past 5 Years
(Consolidated)
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
1,400,000
1,600,000
2018
2019
2020
2021
2022
Expressed in thousands of NTD
Q
Q1
Q2
Q3
Q4
Total
Growth(%)
2018
763,261
897,693
913,353
998,786
3,573,093
-7.2%
2019
846,177
1,010,837
1,048,886
1,031,229
3,937,129
+10.2%
2020
1,034,417
1,108,059
1,045,351
1,117,573
4,305,400
+9.4%
2021
1,101,113
1,149,060
1,120,840
1,233,069
4,604,082
+6.9%
2022
1,237,170
1,481,061
1,549,872
1,583,265
5,851,368
+27.1%
18 19 20 21 22
18 19 20 21 22
18 19 20 21
18 19 20 21 22
22		 Comparison of Quarterly Revenue of Past 5 Years
(Consolidated)
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
1,400,000
1,600,000
2018
2019
2020
2021
2022
Expressed in thousands of NTD
Q
Q1
Q2
Q3
Q4
Total
Growth(%)
2018
763,261
897,693
913,353
998,786
3,573,093
-7.2%
2019
846,177
1,010,837
1,048,886
1,031,229
3,937,129
+10.2%
2020
1,034,417
1,108,059
1,045,351
1,117,573
4,305,400
+9.4%
2021
1,101,113
1,149,060
1,120,840
1,233,069
4,604,082
+6.9%
2022
1,237,170
1,481,061
1,549,872
1,583,265
5,851,368
+27.1%
18 19 20 21 22
18 19 20 21 22
18 19 20 21
18 19 20 21 22
22		 Comparison of Quarterly Revenue of Past 5 Years
(Consolidated)
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
1,400,000
1,600,000
2018
2019
2020
2021
2022
Expressed in thousands of NTD
Q
Q1
Q2
Q3
Q4
Total
Growth(%)
2018
763,261
897,693
913,353
998,786
3,573,093
-7.2%
2019
846,177
1,010,837
1,048,886
1,031,229
3,937,129
+10.2%
2020
1,034,417
1,108,059
1,045,351
1,117,573
4,305,400
+9.4%
2021
1,101,113
1,149,060
1,120,840
1,233,069
4,604,082
+6.9%
2022
1,237,170
1,481,061
1,549,872
1,583,265
5,851,368
+27.1%
18 19 20 21 22
18 19 20 21 22
18 19 20 21
18 19 20 21 22
22		 Comparison of Quarterly Revenue of Past 5 Years
(Consolidated)
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
1,400,000
1,600,000
2018
2019
2020
2021
2022
Expressed in thousands of NTD
Q
Q1
Q2
Q3
Q4
Total
Growth(%)
2018
763,261
897,693
913,353
998,786
3,573,093
-7.2%
2019
846,177
1,010,837
1,048,886
1,031,229
3,937,129
+10.2%
2020
1,034,417
1,108,059
1,045,351
1,117,573
4,305,400
+9.4%
2021
1,101,113
1,149,060
1,120,840
1,233,069
4,604,082
+6.9%
2022
1,237,170
1,481,061
1,549,872
1,583,265
5,851,368
+27.1%
18 19 20 21 22
18 19 20 21 22
18 19 20 21
18 19 20 21 22
22
0
200,000
Q
Q1
Q2
Q3
Q4
Total
Growth(%)
2018
763,261
897,693
913,353
998,786
3,573,093
-7.2%
2019
846,177
1,010,837
1,048,886
1,031,229
3,937,129
+10.2%
2020
1,034,417
1,108,059
1,045,351
1,117,573
4,305,400
+9.4%
2021
1,101,113
1,149,060
1,120,840
1,233,069
4,604,082
+6.9%
2022
1,237,170
1,481,061
1,549,872
1,583,265
5,851,368
+27.1%
Q1 Q2 Q3 Q4 Total Growth(%)
2018 763,261 897,693 913,353 998,786 3,573,093 -7.2%
2019 846,177 1,010,837 1,048,886 1,031,229 3,937,129 +10.2%
2020 1,034,417 1,108,059 1,045,351 1,117,573 4,305,400 +9.4%
2021 1,101,113 1,149,060 1,120,840 1,233,069 4,604,082 +6.9%
2022 1,237,170 1,481,061 1,549,872 1,583,265 5,851,368 +27.1%

8
Note: SYN-TECH CHEM. & PHARM. Co., Ltd. is consolidated into the financial report since 2021.12.08

Note: SYN-TECH CHEM. & PHARM. Co., Ltd. is consolidated into the financial report since 2021.12.08

8

© 2023 SCP, Ltd

==> picture [88 x 81] intentionally omitted <==

Consolidated Balance Sheet

Items 2022 2022 2021 2021 Diff. Annual
changes(%)		 Q
(Expressed in thousands of NTD) Amount % Amount %
Cash and cash equivalents 2,259,381 20.6% 2,564,395 25.4% (305,014) (11.9%)
Accounts receivable 1,479,581 13.5% 1,490,058 14.8% (10,477) (0.7%)
Inventories 1,386,483 12.6% 1,217,528 12.1% 168,955 13.9%
Investments 1,020,599 9.3% 904,243 9.0% 116,356 12.9%
Property, plant and equipment 3,658,581 33.4% 2,658,198 26.3% 1,000,383 37.6%
Others 1,163,634 10.6% 1,260,617 12.5% (96,983) (7.7%)
Total Assets 10,968,259 100.0% 10,095,039 100.0% 873,220 8.6%
Current Liabilities 2,879,832 26.3% 2,716,097 26.9% 163,735 6.0%
Non-current Liabilities 652,826 6.0% 579,328 5.7% 73,498 12.7%
Total liabilities 3,532,658 32.2% 3,295,425 32.6% 237,233 7.2%
Total shareholder’s equity 7,435,601 67.8% 6,799,614 67.4% 635,987 9.4%
Debt Ratio(Liabilities/Assets) 32.2% 32.6%
2023 SCP, Ltd
Note: SYN-TECH CHEM. & PHARM. Co., Ltd. is consolidated into the financial report since 2021.12.08

© 2023 SCP, Ltd

Note: SYN-TECH CHEM. & PHARM. Co., Ltd. is consolidated into the financial report since 2021.12.08

9

Consolidated Cash Flows

==> picture [88 x 81] intentionally omitted <==

Items 2022 2021
(Expressed in thousands of NTD)
Cash at beginning ofyear 2,564,395 1,036,183
Cash flows from operatingactivities 1,227,834 827,034
Acquisition ofproperty,plant and equipment (1,193,533) (213,108)
Cash dividends (446,740) (321,653)
Short and loan-term borrowings 124,014 274,221
Investment and others(Note) (16,589) 961,718
Cash at end ofyear 2,259,381 2,564,395
Free cash flow
(Cash flows from operating activities-Acquisition of property, plant and
equipment)		 34,301 613,926

10

© 2023 SCP, Ltd

Note: In 2021, the cash mainly obtained from the merger into SYN-TECH CHEM. & PHARM. Co., Ltd. on 2021.12.08

1720 SCP achieved a record high net profit after tax and EPS in 2022

==> picture [687 x 369] intentionally omitted <==

----- Start of picture text -----

NTD Thousand
Profit Cash Dividend Stock Dividend EPS
800,000 5.00
4.56
4.50
700,000
3.95
4.00
600,000
3.50
2.93
500,000
3.00
400,000 2.50
2.09 [2.15 ] 2.09 1.95 1.90 2.03 2.09 2.11
1.77 [1.81 1.88 ]
2.00
300,000
1.35 [1.47 1.61 1.73 ]
1.50
2.50
200,000 2.50
1.20 [1.50] [1.25] 1.20 [1.60] 0.50 1.00 1.20 1.00 1.50 1.50 1.60 1.50 1.50 1.80 1.00
100,000
2.50 0.50
0.30 0.30 0.70
0 0.00
© 2023 SCP, Ltd
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [60 x 64] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

11

1777 SYN-TECH achieved a record high net profit after tax and EPS in 2022

NTD Thousand

©2023 SCP, Ltd
0
50,000
100,000
150,000
200,000
250,000
300,000
350,000		 0.50
1.70
2.00 2.40
1.52 1.00 2.30
1.00
1.30
2.00
3.00
3.50 3.50
1.75
3.30 3.50 4.00
1.93
3.00
2.93
3.33
1.74
2.37 2.15
3.38
2.19
1.89
3.10
4.935.20 5.27
1.99
5.125.31
6.21
5.03
6.62
0
1
2
3
4
5
6
7
8
9
Profit
Cash Dividend
Stock Dividend
EPS		 0.50
1.70
2.00 2.40
1.52 1.00 2.30
1.00
1.30
2.00
3.00
3.50 3.50
1.75
3.30 3.50 4.00
1.93
3.00
2.93
3.33
1.74
2.37 2.15
3.38
2.19
1.89
3.10
4.935.20 5.27
1.99
5.125.31
6.21
5.03
6.62
0
1
2
3
4
5
6
7
8
9
Profit
Cash Dividend
Stock Dividend
EPS
0.50
1.70
2.00 2.40
1.52 1.00 2.30
1.00
1.30
2.00
3.00
3.50 3.50
1.75
3.30 3.50 4.00
1.93
3.00
2.93
3.33
1.74
2.37 2.15
3.38
2.19
1.89
3.10
4.935.20 5.27
1.99
5.125.31
6.21
5.03
6.62

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

Q

12

8279 Syngen achieved a record high net profit after tax and EPS in 2022

NTD Thousand

==> picture [633 x 300] intentionally omitted <==

----- Start of picture text -----

Profit Cash Dividend Stock Dividend EPS
400,000 14.00
11.85
350,000
12.00
300,000
10.00
8.77
250,000 7.86 7.95
8.00
6.43
200,000
5.8
6.00
4.69
150,000
3.76
4.00
100,000
3.50
2.04 4.00 5.00
2.00
50,000
1.00 1.00 2.50
3.00
0.50 1.00
0 0.00
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [60 x 64] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

© 2023 SCP, Ltd

13

==> picture [229 x 475] intentionally omitted <==

----- Start of picture text -----

© 2023 SCP, Ltd
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

Agenda

Introduction of Standard Group2022 Operating Results

Future Operation StrategyCorporate Social Responsibility (CSR)

14

Future Milestone

==> picture [697 x 88] intentionally omitted <==

==> picture [115 x 147] intentionally omitted <==

From Taiwan to International From Generics to Better than Generics (BTG)

==> picture [263 x 68] intentionally omitted <==

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [60 x 64] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

15
----- End of picture text -----

© 2023 SCP, Ltd

Significant Business Activities in the Past Two Years

==> picture [88 x 81] intentionally omitted <==

  • Taiwan China Japan • Continue to seek

  • • • During the COVID-19 collaborations with We continue to ship pandemic, effective medications for bronchiolitis pharmaceutical companies.

  • production and sales and oral anti-inflammatory • Strategy: cooperation

  • control led to business and pain relief medications. through technology transfer •

  • growth. CDMO/CMO items are in and import our own branded

  • • progress. SCP, SYN-TECH, and products. •

  • Syngen achieved record Acting as agent to import • In 2022, two import new drugs, with an

  • high EPS in 2022. applications were submitted. expected submission in 2023 and launch in 2025.

  • • In 2023, one agreement was signed, one import application Q was submitted, and a total of five applications were under review.

==> picture [16 x 15] intentionally omitted <==

16

© 2023 SCP, Ltd

Revenue Growth Strate -Taiwan gy

==> picture [127 x 181] intentionally omitted <==

The three companies in the group achieved record high EPS in 2022.

SCP (1720) 4.56 Syn-Tech (1777) 6.62 Syngen (8279) 11.85

 Outstanding Operation

  • We focus on four main areas of business:

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

  • Western medicine formulations, APIs, health supplements, and pharmaceutical chain stores.

  • SCP, Syn-Tech, Syngen, and Your Chance all have outstanding management teams

  • Your Chance(6929) was listed on the Pioneer Stock board in October 2022 and is expected to transfer to the emerging stock market by the end of 2023.

Q

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

17
----- End of picture text -----

© 2023 SCP, Ltd

China Market Trends: Current Market Situation

==> picture [691 x 335] intentionally omitted <==

----- Start of picture text -----

Pharmaceutical
Pharmaceutical companies are refocusing on drugs with clinical
companies: value and being more conservative, after the capital market cooled
Returning to off due to the failure to produce truly innovative drugs despite
various bonuses and subsidies.
fundamentals
Certain mechanisms, such as PD-1 and CDE, have led to an
excessive number of new drugs.
Investment in generic drugs is decreasing, with only well-funded
large pharmaceutical companies actively developing them. Small
Impact of
and medium-sized enterprises and pure pharmaceutical sales
centralized
companies are in a dilemma, fearing short-term difficulty in
procurement recovering their investment and long-term lack of products.
cost control Sales companies are beginning to focus on non-hospital and online
sales platforms that are relatively unaffected by centralized
procurement.
----- End of picture text -----

© 2023 SCP, Ltd

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [60 x 64] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

18
----- End of picture text -----

==> picture [807 x 474] intentionally omitted <==

----- Start of picture text -----

China Market Trends: Current Market Situation
•
Sales were affected by the pandemic in 2020, but recovered in 2021. However, the
second outbreak in 2022 caused another dip in sales.
•
In mid-December 2022, China withdrew its "zero-COVID" policy, causing a rebound in
sales in the pharmaceutical market and even shortages in some regions. It is estimated
that pharmaceutical sales will fully recover in 2023.
(Unit: Hundred million/RMB)
Hospital Pharmacy Overall sales
16000
14063 13782 13664
14000 13313
12931
12000 10984
10386 10465 10298
9715
10000
8000
6000 Q
4000 2927 3079 3216 3317 3366
2000 Source：
www.menet.com.cn 19
0 China (public hospital and brick-and-
2023 SCP, Ltd 2018 2019 2020 2021 2022 mortar pharmacy)
----- End of picture text -----

© 2023 SCP, Ltd

Revenue Growth Strate - China gy

==> picture [72 x 71] intentionally omitted <==

Competitiveness

==> picture [67 x 54] intentionally omitted <==

Bio- Equivalence Execution

  • SCP has successful experience with U.S. and Japan regulatory dossiers

  • One completed

  • Expertise in Fasting & Fed BE design and execution

==> picture [71 x 73] intentionally omitted <==

==> picture [70 x 68] intentionally omitted <==

Medium-term targets

NMPA Consistency Evaluation

  • Self-developed products submission

  • 9 ongoing cases, 5 of which were submitted for evaluation

  • Enhance profit sharing revenue

Cooperation

Strategy

  • Tech-transfer

  • Emphasize export and tech transfer simultaneously

  • Accelerate license acquisition to become MAH

  • Joint ownership of License

  • Cooperative production and marketing

  • Profit-sharing Partnerships

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

Q

  • Self-owned drug licenses and establishment of distribution channel

© 2023 SCP, Ltd

20

Ja an Market Trend p

After 2018, new drugs were no longer eligible for price increases and their prices were adjusted downward each year. This made it difficult for R&D investments to be recovered. Of all the new drugs launched in the US and EU each year, 72% are not available in Japan.

==> picture [6 x 31] intentionally omitted <==

New drug launches are shifting towards rare diseases (those with a patient population of less than 9,999).

==> picture [6 x 32] intentionally omitted <==

==> picture [702 x 233] intentionally omitted <==

----- Start of picture text -----

New Drugs sales changes New Drugs development field changes
不到9,999人 <9,999 10.000人以上不到99,999人 10,000~99,999 100,000人以上 >100,000
Generic drug launch
Sales 100%
Switch to generic drug
50%
0%
© 2023 SCP, Ltd 2011年2013年2015年2017年2019年2020年2021年2022年 2011 2013 2015 2017 2019 2020 2021 2022
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [60 x 64] intentionally omitted <==

----- Start of picture text -----

Q
----- End of picture text -----

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

21
----- End of picture text -----

Japan Market Trend Japan Market Trend
The price of API for drugs has skyrocketed, accounting for approximately60-80%of
the production cost of drugs.
Pharmaceutical companies are actively involved in joint development. About32%of
the products that receive drug licenses each year are developed jointly.
Generic drugs commonly face shortages and controlled shipments, and are affected by
factors such as low prices, logistics warehouse fires, and increased shipping costs due to
epidemics.Once the supply is interrupted, it will be replaced easily
7821
8383
9595
9803
10065
10934
11207
11170
10000
12000
學名藥藥價收載品項數
共同開發品項數
Proportion of joint developed drugs
Category
Shortages
Controlled shipment
Num#
%
Num#
%
2021 Drug shortage and controlled shipment
Joint developed
Listed Generic Drugs
2000
4000
6000
8000		 3024
(31.5%)
3280
(32.5%)
3425
(34.7%)
3519
(35.0%)
3529
(32.3%)
3604
(32.2%)
Brand
34
4.6%
170
7.1%
Generic
686
92.3%
2204
91.8%
Other
23
3.1%
26
1.1%		 Q
0 2010年
2012年
2014年
2016年
2018年
2020年
2021年
2022年
Total
743
100%
2400
100%
2010 2012 2014 2016 2018 2020 2021 2022		 22
©2023 SCP, Ltd

==> picture [338 x 181] intentionally omitted <==

----- Start of picture text -----

學名藥藥價收載品項數 Listed Generic Drugs 共同開發品項數 Joint developed
12000 10934 11207 11170
9595 9803 10065
10000
8383
7821
8000
6000
3024 3280 3425 3519 3529 3604
(31.5%) (32.5%) (34.7%) (35.0%) (32.3%) (32.2%)
4000
2000
0
2010 2012 2014 2016 2018 2020 2021 2022 2010年 2012年 2014年 2016年 2018年 2020年 2021年 2022年
© 2023 SCP, Ltd
----- End of picture text -----

Revenue Growth Strategy - Japan

==> picture [71 x 63] intentionally omitted <==

==> picture [67 x 64] intentionally omitted <==

Strategy

Collaboration Model

  • Agent for brand new drugs.

  • CDMO

  • Collaborating with Japan pharmaceutical company to enter other markets.

  • Japan marketing partner

  • Strategic alliance with API manufacturer.

  • API Vertical Integration with Syn-Tech.

  • Self-owned license

==> picture [69 x 65] intentionally omitted <==

----- Start of picture text -----

•
----- End of picture text -----

Current State

On Going

  • Ongoing export of Montelukast (Asthma) and Celecoxib (Antiinflammatory)

  • CDMO/CMO

  • Common items for China/ Southeast Asia/ Japan are under discussion

  • Obtaining the agency of a new drug for gout, currently in clinical trials, expected to be submitted in 2023 and launched in 2025.

© 2023 SCP, Ltd

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

Q

23

==> picture [818 x 474] intentionally omitted <==

----- Start of picture text -----

US Market Trend
•
In 2021, US market generic drugs accounted for 91% of the total
sales volume, but only 18.2% of the sales revenue.
Sales Volume ratio
Sales Amount ratio
100% 100%
90% 90% 25.2% 23.2% 21.3% 20.0% 19.0% [18.20%]
80% 80%
70% 70%
60% 60%
89.6% 90.6% 90.7% 91.1% 91.3% 91.0%
50% 50%
74.8% 76.8% 78.7% 80.0% 81.0% 81.80%
40% 40%
30% 30%
20% 20% Q
10% 10%
10.4% 9.4% 9.3% 8.9% 8.7% 9.0%
0% 0%
2016 2017 2018 2019 2020 2021 2016 2017 2018 2019 2020 2021
24
Brand drug Generic drug Brand drug Generic drug
© 2023 SCP, Ltd
----- End of picture text -----

==> picture [6 x 31] intentionally omitted <==

US-FDA Dru Com etition Action Plan g p

The bill upgraded by Dec. 2022

Promote the development of generic drugs, improve the efficiency of review and and make the review more approval, process transparent.

Streamline regulatory requirements for the development of difficultto-develop generic drugs to help reduce the time, uncertainty, and cost of drug development.

Strengthen regulatory review and gap filling to avoid delaying the launch of generic drugs due to the brand drug.

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

Q

“Actively encourage the launch of generic drugs”

© 2023 SCP, Ltd

25

Revenue Growth Strate – U.S.A. gy

==> picture [154 x 110] intentionally omitted <==

U.S.A. Market

  • Largest Rx Market, with large proportion of generic drugs.

  • The arduous and costly process of applying license is a remote objective for planning purposes.

==> picture [54 x 54] intentionally omitted <==

Current Status

Strategy

  • Co-develop new products with pharmaceutical companies and dealers.

  • Export of diabetic and amyotrophic lateral sclerosis(ALS) drugs.

  • Two items have been approved by P4 (One item will be launched in 2023).

  • API Vertical Integration with Syn-Tech.

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

Q

==> picture [38 x 38] intentionally omitted <==

----- Start of picture text -----

26
----- End of picture text -----

© 2023 SCP, Ltd

Future Operation Strategy

Future From Taiwan to International From Generics to BTG

2024 2023 、 、 USA Japan

、 China Japan

Core techniques and Increasing oversea professional Oversea marketing Resource proportion 增加海 核心技術 skills to expend & 專業 海外市場操作 practices oversea sales 借力使力 • 外比例 • • Increase resources for Use mature Taiwanese Establish a solid foundation. overseas business.

  • Establish a solid foundation.

  • Use mature Taiwanese technology to create R&D wealth.

  • Quickly generate revenue.

  • Recruit and train international talents.

  • Learn the rules of the game. in various markets.

  • Jointly plan and operate markets with foreign companies.

  • Seek for long-term partners.

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

Q

© 2023 SCP, Ltd

27

==> picture [229 x 475] intentionally omitted <==

----- Start of picture text -----

© 2023 SCP, Ltd
----- End of picture text -----

==> picture [88 x 81] intentionally omitted <==

Agenda

Introduction of Standard Group2022 Operating ResultsFuture Operation Strategy

Corporate Social Responsibility (CSR)

28

Fan Dao Nan Foundation

==> picture [156 x 115] intentionally omitted <==

Introduction to the foundation

  • Established in 1987

  • Endowment Fund: NT$196 Million

  • Annual Budget: NT$12 Million

==> picture [157 x 113] intentionally omitted <==

Principal Activities

  • Cultural and educational development activities

  • Public education affairs

  • Children’s education and happiness

  • Scholarships and Talent Cultivation

==> picture [158 x 114] intentionally omitted <==

Rewards and Honors Received

  • 2011: Special Recognition Award – Ministry of Education

  • 2012: Tainan City Govt. Grant for Scholarship Program

  • 2013: National Special Selection Award for

  • After-School Program – Dept. of Education

  • 2022: Group Award on Social Education Contribution by Ministry Of Education

© 2023 SCP, Ltd

==> picture [88 x 81] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

==> picture [57 x 57] intentionally omitted <==

Q

29

==> picture [807 x 474] intentionally omitted <==

----- Start of picture text -----

2022 Corporate Social Responsibility
Scholarships
Hope After-school Class Sunflower Wednesdays
 Pharmaceutical or related major: 4
universities/ 9 students •Weekday afternoons •Every Wednesday afternoons
High school :8 schools, totaled 146 students
Middle school:60 schools, totaled 752 students •38 schools，2,635 students •13 Schools，726 students
 Elementary school: 234 schools, totaled 2,732
students
NTD 6.58 million NTD 2.04 million NTD 0.65 million
Other Sponsorships Meal-Assistance
Charity
 organizations.Sponsor 13 public welfare  Provided 6,775 meals  SCP Children’s Drawing Competition
 SCP National Table Tennis
Competition Q
NTD 0.65 million NTD 0.54 million 2022 Suspended due to Covid-19
30
2023 SCP, Ltd
----- End of picture text -----

© 2023 SCP, Ltd

Senior Gym in Taiwan – Athletic Trainin and Health Center g

==> picture [316 x 179] intentionally omitted <==

==> picture [468 x 389] intentionally omitted <==

----- Start of picture text -----

Q
31
----- End of picture text -----

  • In 2022

  • The cumulative number of users is 76,826.

  • Hosted 20 health and wellness seminars about nutrition and fitness topics.

© 2023 SCP, Ltd

==> picture [236 x 475] intentionally omitted <==

----- Start of picture text -----

© 2023 SCP, Ltd
----- End of picture text -----

Q & A

==> picture [88 x 81] intentionally omitted <==

32

More from S.C.P.C

Regulatory Filings 2026
Jun 2
AGM Information 2026
May 19
Interim / Quarterly Report 2026
May 14
Regulatory Filings 2026
May 14
Interim / Quarterly Report 2026
May 13
Interim / Quarterly Report 2026
May 13
Regulatory Filings 2026
May 13
Regulatory Filings 2026
May 13
Interim / Quarterly Report 2026
May 13
Regulatory Filings 2026
May 12
View all filings →